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a b s t r a c t
In this work the study of Calf Thymus DNA interaction with several Cu(L-dipeptide) complexes was
reported. The binding stoichiometry (Cu(mmol)/DNAmol base) was determined and in an attempt to clar-
ify the binding mode, EPR and CD experiments were performed. All the studied complexes interacted
with DNA, in a more selective way than [Cu(H2O)6]
2+, being the [Cu(ala-phe)] the complex with the high-
est interaction. The EPR experiments suggested that the monomeric species formed in solution were
coordinated through a nitrogen atom of the DNA bases (inner-sphere binding) and the CD studies showed
structural changes upon the DNA–complex interaction. Besides, the ratio Cu(mmol)/DNAmol base
obtained by the binding stoichiometry experiments was close to that found by EPR and CD determina-
tions. The effect on cell proliferation determined by the crystal violet bioassay on UMR106 rat osteosar-
coma-derived cells showed that the [Cu(ala-phe)] complex exerted an antiproliferative action against this
tumor line.
 2009 Elsevier Ltd. All rights reserved.
1. Introduction
The interaction of metal complexes with nucleic acids and their
constituents has been a subject of interest in bioinorganic chemis-
try, especially since the discovery of cisplatin and their analogues.
These studies have been useful for the development and the com-
prehension of the activity of new chemotherapeutic agents de-
signed for the treatment of numerous diseases [1–3]. Many of
these chemotherapeutic agents act by inhibition of the synthesis
of the deoxyribonucleic acid (DNA), a natural target due to its pre-
dominant role in cellular replication. One way to achieve this inhi-
bition is by direct DNA binding in either a noncovalent interaction
by intercalation, groove-face binding or external electrostatic bind-
ing or a covalent interaction due to an outer-sphere or inner-
sphere binding and (or consecutive) strand breakage [4,5].
In particular, in the search for new drugs the proposal that com-
plexes based on essential metals may be less toxic than those with
non essential ones led to the study of copper based drugs, some of
them having an important cytotoxic effect [6–8]. Consequently, ac-
tive copper compounds and their interaction with DNA have at-
tracted great interest [5,9–11]. These studies have mostly used
methods that focus on changes in the DNA structure as electronic
absorption titration, ﬂuorescence spectroscopy, viscosity measure-
ments and circular dichroism, among others. For instance, chemo-
therapeutic copper complexes with polypyridil ligands showed an
important interaction with DNA as intercalators as determined by
UV–Vis and circular dichroism (CD) spectroscopies and viscosity
[3]. Moreover, Sarkar’s group studied the DNA interaction of Cu(II)
complexes with piroxicam and meloxicam (anti-inﬂammatory
drugs) which exhibited anticancer activity by UV–Vis and circular
dichroism (CD) spectroscopies. They showed that their complexes
bind strongly to DNA-backbone possibly with intercalation [12].
On the other hand, there is much less work using methods
based on properties related to the metal ion. In this area relevant
studies were performed by Chikira’s group that provided informa-
tion on the binding of copper complexes with amino acids or pep-
tides to DNA ﬁbers by electronic paramagnetic resonance (EPR)
[13–20].
As a part of our research on metal-based drugs we have studied
several copper complexes with oligopeptides as potential antitu-
moral agents encouraged by the antecedents in the literature
[21,22]. In particular, we have synthesized and structurally charac-
terized in solid state and in water solution a series of copper com-
plexes with dipeptides [23–30] and analysed their magnetic
interactions [31,32].
Due to these previously reported antecedents and with the aim
of obtaining structural information about the interaction of DNA
with copper-dipeptide complexes we explored changes in the
environment of the copper ion and in the DNA upon coordination.
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In particular, the study of the DNA interaction with several Cu(L-
dipeptide) complexes previously characterized by our research
group was performed. Several dipeptides commercially available
were selected in an effort to include ligands with inverted se-
quences of aminoacids and to cover a series containing aminoacids
with different sizes. The aim of this selection was to perform a
screening that provides structural information useful for biggest
systems. Firstly, the direct quantiﬁcation of the amount of copper
bound to the DNA (binding stoichiometry) was measured. Sec-
ondly, EPR experiments were made with the complex that pre-
sented the best binding stoichiometry and with two complexes
that presented medium interaction, in order to test whether there
was any change in the Cu(II) coordination sphere when binding to
the DNA. CD technique was used to explore the distortion intro-
duced in the DNA structure upon binding with complexes or the
distortion in the Cu(dipeptide) complexes.
Besides, to evaluate potential pharmacological activity of the
complexes, a cell proliferation assay on UMR106 rat osteosar-
coma-derived cells was performed.
2. Materials and methods
2.1. Synthesis of the complexes and analytical characterization
The copper (II) complexes with L-dipetides (SIGMA) ala-ala, ala-
val, ala-ile, ala-leu, ala-thr, ala-phe, ala-tyr, phe-ala, phe-leu, phe-
phe, val-phe, val-gly were obtained and characterized as described
previously [26,27,29,30].
Table 1 summarizes the stoichiometry and analytical data for
the Cu(II) complexes. Elemental analysis was performed with a
CARLO ERBA EA 1108 equipment.
2.2. Spectroscopic measurements
Electronic absorption spectra of aqueous solution samples were
recorded on a Milton Roy Spectronic 3000 spectrophotometer,
using 1-cm path length quartz cells.
The copper concentration was measured by atomic absorption
spectroscopy using a Perkin–Elmer 5000 instrument, with a Pho-
tron lamp for copper analysis, at 325 nm with air/acetylene ﬂame.
X-band (9.5 GHz) EPR measurements were carried out on frozen
aqueous solutions using a Varian E109 spectrometer and cavity
with 100 kHz ﬁeld modulation. The measurements were per-
formed at N2 liquid temperature. The g-values were obtained from
spectral simulations using the QPOW program [33].
The CD spectra were recorded using a Jasco 720 instrument in a
1-cm path length quartz cell, in the 200–300 nm range.
2.3. Determination of the stoichiometry of the interaction
Cu(II)dipeptide–DNA
The technique used in order to determine the stoichiometry of
the interaction of the complexes with DNA was adapted from
Mahnken et al. [34]. An aqueous solution of Calf Thymus DNA (SIG-
MA) (c.a. 1.7 mg/mL, 1 mL) was allowed to react with an aqueous
solution of Cu-dipeptide (c.a. 1 mM, 1 mL) for 24 h at 37 C.
The DNA was precipitated afterwards by addition of absolute
ethanol (4 mL) and an aqueous solution of NaCl (2 M, 0.2 mL),
and it was centrifuged (30 min at 50 rpm). The supernatant was
discarded. The precipitate was dissolved in 2 mL of H2O. This pro-
cess was repeated three times. DNA and copper concentrations
were monitored in the ﬁnal solution. DNA concentration was
determined at 260 nm using eM = 6000 M1 cm1. Copper concen-
tration was measured by atomic absorption spectroscopy as de-
scribed in Section 2.1. The solubility of the complexes was
checked in the conditions of the precipitation of the DNA. The
interaction was expressed as the ratio: Cu(mmol)/DNA(mol base).
2.4. Cu(II)dipeptide–DNA binding: characterization by EPR
measurements
The EPR spectra of an aqueous solution of Calf Thymus DNA
(SIGMA, 2.45 mg/mL) in presence of increasing amounts of copper
complexes were recorded. The dilution scheme for each Cu(II)
complex covered a 10–500 lM range, while the concentration of
the DNA solution varied from 500 to 700 lM in DNA bases (pH
7). After each addition of copper complex the mixture was allowed
to mix for 15 min at room temperature and then an aliquot was
frozen at N2 liquid temperature in order to register the EPR
spectrum.
2.5. Cu(II)dipeptide–DNA binding: characterization by CD
measurements
The CD spectra of an aqueous solution of Calf Thymus DNA (SIG-
MA) in presence of increasing amounts of copper complexes were
recorded. The dilution scheme for each Cu(II) complex covered a
0.5–5 lM range, while the concentration of the DNA solution
(DNA concentration was determined at 260 nm using eM = 6000)
remained approximately constant at 50 lM in DNA bases (pH 7).
As the data were obtained in excess of DNA, the total molar con-
centration remained nearly constant in all the spectra of each com-
plex. This enabled us to perform a Job analysis of the data at
218 nm in order to estimate a binding constant for DNA–[Cu-pep-
tide] [35].
Table 1
Stoichiometry, code and analytical data for the Cu(II) complexes.
Complex code Complex stoichiometry %C %N %H
Calc. Exp. Calc. Exp. Calc. Exp.
1 [Cu(ala-ala)]2H2O 27.93 27.57 10.86 10.41 5.40 4.89
2 [Cu(ala-val)] 38.44 38.40 11.21 11.15 5.60 5.66
3 [Cu(ala-ile)] 40.94 40.85 10.61 10.55 6.06 6.18
4 [Cu3(ala-leu)3(H2O)3(CO3)]PF6H2O 31.40 32.23 7.85 8.17 5.54 6.09
5 [Cu(ala-thr)]1/2H2O 32.22 32.30 10.74 10.66 4.98 5.05
6 [Cu(ala-phe)]1/2H2O 48.35 48.15 9.40 9.30 4.70 4.81
7 [Cu(ala-tyr)]H2O 43.40 43.33 8.44 8.54 4.82 4.98
8 [Cu(phe-ala)]1/2H2O 46.93 47.12 9.13 9.19 4.89 4.23
9 [Cu(phe-leu)] 53.01 53.21 8.24 8.52 5.93 6.26
10 [Cu(phe-phe)] 57.82 57.42 7.49 7.57 4.85 4.76
11 [Cu(val-phe)] 51.60 51.96 8.60 8.71 5.57 6.01
12 [Cu(val-gly)] 35.67 35.92 11.88 11.96 5.13 5.58
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2.6. Cell proliferation assay
Due to the fact that [Cu(ala-phe)] presented the higher interac-
tion with DNA, it was selected to study the antiproliferative activ-
ity. The effect of the copper salt and [Cu(ala-phe)] complex over
the cell proliferation was study in a model of osteoblastic tumoral
UMR106 cells.
UMR106 rat osteosarcoma-derived cells were grown in DMEM
supplemented with 100 U/ml penicillin, 100 lg/ml streptomycin
and 10% (v/v) serum bovine fetal (FBS) at 37 C, 5% CO2. When
70–80% conﬂuence was reached, cells were subcultured using
0.1% trypsin 1 mM EDTA in Ca2+–Mg2+ free phosphate buffered sal-
ine (PBS) (11 mM KH2PO4, 26 mM Na2HPO4, 115 mM NaCl, pH:
7.4). For experiments, cells were grown in 24-well plates. When
cells reached 70% conﬂuence, the monolayers were washed twice
with DMEM and were incubated in different conditions according
to the experiment.
A mitogenic bioassay was carried out as described by Okajima
with some modiﬁcations [36].
Brieﬂy, cells were grown in 48-well plates. When cells reached
60% conﬂuence, the monolayers were washed twice with serum-
free DMEM and were incubated with different concentrations of
CuSO4 or Cu-complex. The monolayers were washed with PBS buf-
fer and ﬁxed with 5% glutaraldehyde/PBS at room temperature for
10 min. Then, they were stained with 0.5% crystal violet/25% meth-
anol for 10 min. After that, the dye solution was discarded and the
plate was washed with water and dried. The dye taken up by the
cells was extracted using 0.5 ml/well 0.1 M glycine/HCl buffer,
pH 3.0/30% methanol and transferred to test tubes. Absorbance
was read at 540 nm after a convenient sample dilution [37].
3. Results and discussion
3.1. Determination of the stoichiometry of the interaction
Cu(II)dipeptide–DNA
The results of the binding stoichiometry of Cu(II)dipeptide–DNA
are shown in Table 2. As shown in Table 2, the stoichiometry of
binding depends on the complex, from what it is possible to as-
sume that it is the Cu(II)dipeptide complex, and not only the free
copper ion that interacts with DNA. The [Cu(H2O)6]2+ complex
interacts with DNA at a higher extent (>150 (mmol)/DNA(mol
base)), probably in a less selective way interacting also with phos-
phate groups due to the positive charge.
All the studied complexes showed interaction, in a lower, and
possibly more selective way than Cu(II) aqua ion. The extent of
the interaction depended on the dipeptide ligand. The [Cu(ala-
phe)] complex presented the highest binding stoichiometry while
the rest of the series [Cu(ala-X)] (X = different aminoacids) showed
signiﬁcantly lower values. Besides, the interaction of [Cu(phe-ala)]
was almost four times smaller than that of the [Cu(ala-phe)]. It
might be possible that the phenyl ring (without substituents) in
the second aminoacid is important in the interaction when the ﬁrst
aminoacid is alanine. Another observation is that in the complexes
with a voluminous ﬁrst aminoacid in the dipeptide ligand the
interaction with DNA seems to be disfavoured. This is the case of
[Cu(phe-ala)], [Cu(phe-leu)], [Cu(phe-phe)], [Cu(val-phe)] and Cu(-
val-gly)].
Based on these results, [Cu(ala-phe)] that presented the best
binding stoichiometry and [Cu(ala-val)] and [Cu(val-phe)] that pre-
sented medium interaction, were chosen for carrying out EPR and
CD experiments with the aim to obtain structural information of
the interaction.
3.2. Cu(II)dipeptide–DNA binding: EPR measurements
EPR experiments were carried out with solutions of the com-
plexes [Cu(ala-phe)], [Cu(ala-val)], and [Cu(val-phe)]. Moreover,
EPR spectra of DNA solution in presence of increasing concentra-
tions of the Cu-dipeptide complexes were also recorded (see Sec-
tion 2.3). The Fig. 1 shows the EPR spectra of a solution of free
[Cu(ala-phe)] and solutions of this complex in presence of DNA
at various mmol Cu(ala-phe)/mol bases DNA ratios. Besides, the
spectral simulations are included in Fig. 1. Similar results were ob-
tained studying the spectra of [Cu(ala-val)], and [Cu(val-phe)] in
presence of DNA.
[Cu(ala-phe)] (Fig. 1A) in frozen solution presented an EPR spec-
trum characteristic of coupled Cu(II) ions with a single resonance
around g  2 (H  310 mT) [30,39,40] whereas the spectrum of
the Cu(ala-phe) complex with DNA at low mmol Cu(ala-phe)/
DNA mol bases ratios (Fig. 1B) is the typical spectrum of
Table 2
Binding stoichiometry expressed as Cu(mmol)/DNA(mol base).
Complex number Complex stoichiometry Cu(mmol)/
DNA(mol base)
1 [Cu(ala-ala)]2H2O 11
2a [Cu(ala-val)]a 9
3a [Cu(ala-ile)]a 14
4 [Cu3(ala-leu)3(H2O)3(CO3)]PF6H2O 20
5 [Cu(ala-thr)]1/2H2O 14
6a [Cu(ala-phe)]a 42
7 [Cu(ala-tyr)]H2O 10
8 [[Cu(phe-ala)]1/2H2O 11
9a [Cu(phe-leu)]a 13
10a [Cu(phe-phe)]a 2
11 [Cu(val-phe)] 8
12 [Cu(val-gly)] 10
a Previously reported [38].
Fig. 1. Experimental (lower trace) and simulated (upper trace) X-band EPR spectra
of a frozen solution of: (A) [Cu(ala-phe)] and [Cu(ala-phe)] in presence of DNA at (B)
30, (C) 110, and (D) 500 mmol Cu(ala-phe)/DNA mol bases.
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monomeric Cu(II) complexes where the four hyperﬁne lines arising
from the interaction of the S = 1/2 electron spin with the I = 3/2
copper nucleus are observed. This result showed that, at low Cu-
dipeptide per DNA ratios (low copper complex levels), the magnet-
ically coupled structure of the Cu-dipeptide complex is lost due to
the coordination of the Cu-dipeptide monomer with the DNA mol-
ecule. The g values obtained from simulations of the spectrum at
low mmol Cu(ala-phe)/mol bases DNA are: g// = 2.217, g\ = 2.048,
A// = 550 MHz and A\ = 35 MHz.
With the aim to obtain structural information Peisach’s pro-
posal was used [19,41]. The magnitude of A// and g// was interpo-
lated in the Peisach graph and the nature of the coordinating
atoms in the equatorial plane was assigned. Our A// and g// values
are similar to those reported for Cu(II) coordinated through three
N atoms and one O atom (N3O).
Fig. 2 shows the Cu(II) environment in solution as presented in
our previous work [38].
As shown in Fig. 2, in the free complex Cu(II) is coordinated
through two N atoms and two O atoms in the equatorial plane.
After the interaction with DNA, the EPR spectra suggest that the
copper ion is equatorially coordinated through three N atoms
and one O atom. This behaviour would show that one O atom from
the copper environment is replaced by one N from a DNA base (in-
ner-sphere binding).
When the Cu-dipeptide per DNA ratios increases (Fig. 1C and D)
a spectrum of coupled Cu(II) ions appears superposed to the mono-
meric signal. The spectra in Figs. 1C and D could only be satisfacto-
rily simulated when two spectral components were included in the
ﬁtting protocol using the QPOW program: the spectrum of the
polymeric species (Cu(ala-phe) alone) and the spectrum of the
monomeric specie (Cu(ala-phe) bonded to DNA), described above.
The existence of two spectral components supports the hypoth-
esis that the DNA is able to bind only a small amount of Cu(dipep-
tide), and the remaining Cu(dipeptide) exists as free complex in
solution (not coordinated to the DNA).
3.3. Cu(II)dipeptide–DNA binding: characterization by CD
measurements
Circular dichroism experiments were carried out with [Cu(ala-
phe)], [Cu(ala-val)] and [Cu(val-phe)] in (a) copper complex solu-
tions and (b) copper complex solutions in presence of DNA. The
aim of these experiments was to conﬁrm the interaction and deter-
mine whether the DNA or the Cu(dipeptide) complex experi-
mented structural changes due to the Cu(dipeptide)–DNA
interaction.
(a) The spectra of aqueous solutions of the Cu(dipeptide) com-
plexes were registered at increasing concentrations. As an
example, the inset of Fig. 3 shows the spectra of Cu(ala-
phe) complex. As expected, the ellipticity at 218 nm (maxi-
mum wavelength) linearly increases with the concentration,
as shown Fig. 3, with a molar ellipticity of 765 M1 cm1.
Similar results were obtained for the complex [Cu(val-
phe)] (molar ellipticity at 218 nm: 1190 M1 cm1) while
complex [Cu(ala-val)] does not show any signiﬁcant elliptic-
ity at 218 nm (15 M1 cm1).
(b) The spectra of a DNA solution in presence of increasing con-
centrations of Cu(dipeptide) complexes were registered.
Fig. 4 shows the spectra obtained for the [Cu(ala-phe)]–
DNA system. Similar results were obtained with the
[Cu(val-phe)] complex.
Fig. 4 presents the ellipticity of the system at 218 nm versus
[Cu(ala-phe)] concentration.
It can be observed that the ellipticity at 218 nm does not in-
crease linearly with the [Cu(ala-phe)] concentration, as would be
expected if there were no interaction between the [Cu(ala-phe)]
complex and the DNA. At low Cu(dipeptide) concentration (that
is, low mmol [Cu(ala-phe)]/mol bases DNA ratio) the ellipticity al-
most does not increase with the increment of the Cu(dipeptide)
concentration. As the ratio is increased, the ellipticity increases,
showing a molar ellipticity similar to that of the free Cu(dipeptide)
complex. This may be explained considering that at low mmol
Fig. 2. Scheme of the Cu(II) environment of the Cu-dipeptide complexes in solution.
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Fig. 3. Ellipticity of [Cu(ala-phe)] at 218 nm vs. concentration. Inset: CD spectra of
[Cu(ala-phe)].
Fig. 4. Ellipticity of the [Cu(ala-phe)]-DNA system at 218 nm vs. [Cu(ala-phe)]
concentration. Inset: selected CD spectra of DNA and DNA in presence of [Cu(ala-
phe)] (with mmol [Cu(ala-phe)]/mol bases DNA ratios from 5 to 55).
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[Cu(ala-phe)]/mol bases DNA ratio all the Cu(dipeptide) complex
added is bonded to the DNA. The coordination with DNA induces
structural changes with the consequently quenching of the com-
plex ellipticity. As the mmol Cu(dipeptide)/mol bases DNA ratio
is increased, the DNA is not more able to bind the Cu(dipeptide)
complex, therefore the system behaves as if there were no interac-
tion between the excess of Cu(dipeptide) complex and the DNA. In
the Cu(dipeptide) concentration range of 8.9–13.4 lM (where we
observed the slope change), the Cu(mmol)/DNA(mol base) ratio is
18–32 mmol Cu/DNA (mol base). Although the binding stoichiom-
etry presented in Section 3.1 (42 Cu(mmol)/DNA(mol base)) is not
included in this range it is still comparable and supports the pro-
posal of the DNA saturation.
In the case of the [Cu(ala-val)] complex the results are different
from the previous ones, as shown in Fig. 5.
As the complex has a very low molar ellipticity at 218 nm, the
ellipticity of a solution of DNA with increasing concentrations of
[Cu(ala-val)] should slightly increase at this wavelength. On the
contrary, a decrease in the signal at 218 nm was observed. This re-
sult shows that the molar ellipticity of the DNA decreases in pres-
ence of [Cu(ala-val)], as previously reported for metallic complexes
which bind to DNA [41]. This behaviour suggests a structural
change in the DNA. It is possible that in the case of the complex
[Cu(ala-phe)] there is also a decrease in the molar ellipticity of
the DNA, which is masked by the decrease in the ellipticity of
the complex bounded to the DNA.
In relation to the binding constant, the obtained values for
[Cu(ala-phe)] and [Cu(val-phe)] were 1.2  104 and 5.9 
103 M1, respectively. These results are of the same order that
the corresponding ones for complexes with biological activity re-
ported in the bibliography [42,43].
The spectra of [Cu(ala-val)] does not show enough differences
to estimate a binding constant.
3.4. Cell proliferation assay
The obtained results are shown in Fig. 6. As can be seen from the
ﬁgure, at concentrations lower than 50 lM, the complex do not ex-
ert any inhibition on cell proliferation since no differences versus
basal results could be observed. At higher doses, the complexes
and the copper salt caused different inhibition of cell growth in a
dose response manner. [Cu(ala-phe)] showed the greatest cell pro-
liferation inhibition at the highest concentration (500 lM) where
45% cell survival could be detected when the osteosarcoma cells
were incubated with this complex.
4. Conclusions
This work provided information about the interaction of a series
of Cu(dipeptide) complexes with Calf Thymus DNA using different
methodologies. All the studied complexes showed interaction, in a
lower, and possibly more selective way than Cu(II) aqua ion. The
extent of the interaction depended on the dipeptide ligand.
Interestingly, the EPR and CD studies suggested that the DNA
binds a ﬁxed amount of the Cu(dipetide) complex (which is coor-
dinated to the bases of the DNA) up to saturation. Moreover, the
systems start to show saturation at a mmol Cu(dipeptide)/mol
bases DNA ratio close to that obtained in the binding stoichiometry
values.
The inhibitory effect caused by [Cu(ala-phe)] on cell prolifera-
tion in the cultures of UMR106 osteoblasts is encouraging for fu-
ture studies on the bioactivity of this complex with other
tumoral cell lines since it may have potential application as antitu-
moral agent.
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